{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"46","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Duration of response (DOR) was defined as the time from response (complete remission, partial remission or hematologic improvement) to progression or death of any cause. Responding and alive patients were censored at the date of last follow-up. The median DOR with 95% CI was estimated using the Kaplan Meier method.\n\nResponse was measured by International Standardized Response Criteria for MDS (described in above outcome measure).","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with MDS receive treatment with vatalanib.\n\nvatalanib: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \\> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)","id":"OG000","title":"Vatalanib"}],"paramType":"MEDIAN","populationDescription":"Per the description, only patients who achieved a response were evaluable for this outcome.","reportingStatus":"POSTED","timeFrame":"5 yrs","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}